Clear Street raised the firm’s price target on Summit Therapeutics (SMMT) to $33 from $30 and keeps a Buy rating on the shares following the Q2 report. The firm views the earnings print as “largely uneventful” with no fundamental changes on Summit’s research and development programs. Clear Street continues to view ivonescimab as the “front-runner in a novel class of medicines with several multi-billion-dollar oncology opportunities.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SMMT:
- Ivonescimab’s Promising Potential to Outperform KEYTRUDA: A Strong Buy Recommendation
- Summit Therapeutics Reports Q2 2025 Progress and Financials
- Closing Bell Movers: Green Dot up 20% after Q2 beat and raise
- Summit Therapeutics Amends Stock Distribution Agreement
- Summit Therapeutics reports Q2 non-GAAP EPS (12c) , consensus (7c)